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Abstract The defined daily dose (DDD) as defined by the
World Health Organization (WHO) has been the most
frequently used unit of measurement to measure antibiotic
use. However, measuring antibiotic use in paediatrics is a
problem as the WHO DDD methodology is not applicable in
children (aged >1 month) due to the large variation in body
weight within this population. Based on the narrow range of
body weights in the neonatal population, we therefore aimed
to develop a set of neonatal DDDs for antibiotics. Eight well-
respected (inter)national sources for dosagerecommendations
of antibiotics in children and neonates were consulted for the
assumed maintenance dose of the ten most frequently used
antibiotics in neonatal intensive care units in its main
indication for neonates. A set of neonatal DDDs for ten
commonly used antibiotics in neonates based on an assumed
neonatal weight of 2 kg was proposed. Primarily in children
DDDs are not applicable to quantify antibiotic use since there
is large variation in body weight. In the neonatal population,
however,basedonitsnarrowrangeofbodyweightsandwhen
access to patient level data is not available, neonatal DDDs
can be used as a unit of measurement.
Detailed quantitative and qualitative knowledge of antibi-
otic use is essential to implement strategies for reducing
overuse, underuse and misuse of antibiotics in order to
address the threat posed by resistant microorganisms.
Antibiotic use in hospitals can be quantified using several
methods. The defined daily dose (DDD) as assigned by the
World Health Organization (WHO) has been the most
commonly used unit of measurement to quantify (e.g. as the
number of DDDs used per 100 hospital days) in various
settings and is particularly recommended to compare drug
use between (international) settings, and has it shown its
value for this purpose [1, 2]. The DDD is the assumed
average maintenance dose per day for a drug in its main
indication for adults and is commonly expressed with a
certain population size denominator such as patient days,
bed days, admission days, inhabitant days. The popularity
of the DDD mainly originates from its general applicability
and its advantage that comparison of the amount of drug
use between different (international) settings and between
different drugs based on grouped dispensing data is
possible without requiring utilization data on the individual
patient level. The main disadvantage is that the DDD
neither reflects the recommended, nor the actual prescribed
daily dosage (PDD) for individual patients or specific
patient populations [3–7]. Hence, in an ideal situation, the
actual consumption of antibiotics should be measured at the
level of the individual patient and subsequently aggregated
over patient groups and settings. This gives more precise
estimates but more importantly also allows study of
associations on an individual patient level between
patient characteristics, setting characteristics (e.g. antibi-
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comes, including antibiotic resistance [4].
One of the other main shortcomings of the DDD
methodology is its applicability in paediatrics. In an
editorial commentary, Monnet concluded that in addition
to the revision of WHO DDD, more research is needed
to address other problems, such as the difficulty in
measuring antibiotic use in children in those hospitals
where data at patient level are not available [5]. Problems
arise because dosing of antibiotics in children is based on
body weight. Therefore, in order to calculate a paediatric
DDD, an average body weight for the paediatric popula-
tion needs to be assumed. However, in our opinion, this
methodology is questionable as there is a large variation in
body weight within the paediatric population. This view is
supported by the WHO International Working Group for
Drug Statistics Methodology’s publication ‘Guidelines for
ATC classification and DDD assignment’ [8]. In this, the
WHO states that it is impossible to define paediatric
DDDs because dose recommendations for use in children
vary according to age and body weight (and setting).
Furthermore, many drugs used in paediatrics are not even
approved for such use and dosing information is not
available. In response to the WHOs negative comments
about paediatric DDDs, several alternative measurement
systems for antibiotic use in children have been proposed,
e.g. an estimation of antibiotic exposure by controlling for
patient weight and amount of wasted drug [9, 10].
Nevertheless, regarding the issue on variation in body
weight, one should distinguish children (>1 month of age)
from neonates (<1 month of age) as the variation in body
weight in children (mean body weight at age 1 month is 4.2 kg
[11]; mean body weight at age 17 years is 60 kg [12]) is larger
compared to the neonatal population (mean body weight
2.1 kg ± 1.0, based on own data). Consequently, in our view
the disadvantage of the DDD methodology in paediatrics is
more relevant for children than for neonates. Therefore, we
aimed to devise a set of neonatal DDDs for antibiotics. We
consulted eight well-respected (inter)national sources for
dosage recommendations of antibiotics in children and neo-
nates for the assumed maintenance dose of the ten most
frequently used antibiotics in NICUs in its main indication for
neonates (i.e. neonatal sepsis) (Table 1)[ 13]. Considering
these antibiotics we did not find discrepancies in the dosage
recommendations between the various evaluated sources. In
addition, this overview of assumed maintenance dosages
was evaluated and approved by two external experts: a
hospital pharmacist and a paediatrician-infectious disease
specialist. As a result, we propose a set ofneonatalDDDs for
commonly used antibiotics in neonates based on an assumed
neonatal weight of 2 kg (Table 1). Regarding these proposed
neonatal DDDs, one should, however, take into account the
general limitations of the DDD but also limitations specific
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1302 Eur J Clin Microbiol Infect Dis (2010) 29:1301–1303to this patient group such as the policy on handling of waste
of unused antibiotics in a NICU setting. After all, waste of
unused antibiotics would not reflect a real estimate of
neonatal DDDs.
Obviously, our proposed neonatal DDDs do not alter the
fact that there is a lack of data on antibiotic use on the
individual patient level. Yet, with the increasing use of
computerised medical information systems it will be consid-
erablyeasiertogetaccesstodataonthe level oftheindividual
patient,suchasdaysoftherapy(DOT).DOTisnotinfluenced
by discrepancies between the DDD and the PDD, by changes
in the WHO assigned DDD and is independent of age- and
weight-related differences in dosage [7, 14]. A major
disadvantage of this parameter is, however, that currently
such detailed data on the individual patient level are not
readily available. Moreover, if one would like to link data on
antibiotic use to resistance, preferably both units of
measurement, DOT (independent of dosage) and DDD
(dependent of dosage), should be used, since it is unidenti-
fied which of these measurement methods is most predictive
of resistance [7]. A recent study has shown that repeated
and/or prolonged antibiotic use in neonates resulted in an
increase of hospital-acquired, antibiotic-resistant organisms
such as methicillin-resistant Staphylococcus aureus,
vancomycin-resistant Enterococcus, and multidrug-resistant
Gram-negative rods [15].
In conclusion, in order to quantify antibiotic use, the
DDD methodology is not applicable in the paediatric
population, mainly in children aged between 1 month
and 18 years, due to the large variation in body weight
within this population. Although, in the neonatal popu-
lation, until patient level data are widely available and
based on its narrow range of body weights, we suggest,
illustrated by the example of antibiotics, that the neonatal
DDD (nDDD) is a good alternative unit of measurement,
both in research and for benchmarking purposes.
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